Xvivo Perfusion AB (publ) (STO:XVIVO)

Market Cap	6.97B +34.1%
Revenue (ttm)	895.23M +8.8%
Net Income	88.57M -20.5%
EPS	2.81 -20.0%
Shares Out	31.50M
PE Ratio	78.03
Forward PE	47.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,679
Open	217.00
Previous Close	219.40
Day's Range	217.00 - 223.40
52-Week Range	160.10 - 314.80
Beta	1.47
Analysts	Strong Buy
Price Target	321.60 (+45.26%)
Earnings Date	Oct 22, 2026

About Xvivo Perfusion AB

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1998
• Employees: 197
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: XVIVO

Financial Performance

In 2025, Xvivo Perfusion AB's revenue was 812.17 million, a decrease of -1.25% compared to the previous year's 822.42 million. Earnings were 25.16 million, a decrease of -85.39%.

Analyst Summary

According to 4 analysts, the average rating for XVIVO stock is "Strong Buy." The 12-month stock price target is kr 321.60, which is an increase of 45.26% from the latest price.

Price Target

kr 321.60

(45.26% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 15, 2026

Data Sources Report a data error